Stock Events

Stock Events

Agenus 

$8.24
225
+$0.00+0% Friday 20:00
+$0.01+0.12%Friday 22:49After hours

Statistics

Day High
8.26
Day Low
8.23
52W High
8.36
52W Low
2.77
Volume
26,978
Avg. Volume
-
Mkt Cap
370.88M
P/E Ratio
1.63
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.54
-0.89
0.77
2.42
Expected EPS
-0.01
Actual EPS
N/A

Financials

-0.09%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
114.2MRevenue
-101,000Net Income

Analyst Ratings

19.50Average Price Target
The highest estimate is 25.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGEN. It's not an investment recommendation.
Apple
43
AAPL
Realty Income
34
O
Microsoft
32
MSFT
Tesla
30
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. competes in the immuno-oncology space, offering therapies that directly compete with Agenus' cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a leader in cancer immunotherapy, with products that compete in the same market as Agenus' therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cancer immunotherapy market, particularly in CAR-T therapies, which could be seen as alternative treatments to Agenus' offerings.
Novartis
NVS
Mkt Cap292.35B
Novartis competes in the oncology market, including the development of CAR-T cell therapies, which are in direct competition with Agenus' cancer immunotherapies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a strong presence in oncology and immune-oncology, offering treatments that could compete with Agenus' portfolio.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio, including immunotherapies that compete with Agenus' cancer treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, is a major player in oncology and offers several immunotherapies that compete with Agenus' products.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a growing portfolio in oncology, including immunotherapies that could compete with Agenus' treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in the development of cancer immunotherapies, competing in the same space as Agenus.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer immunotherapies, making it a competitor to Agenus.

About

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Show more...
CEO
Garo H. Armen
Employees
81
Country
United States
ISIN
US00847G8042
WKN
000A403RK

Listings

F
DE
AJ8.F
MU
DE
AJ81.MU
STU
DE
AJ81.STU
MU
DE
AJ8.MU

0 Comments

Share your thoughts

FAQ

What is Agenus stock price today?▼
The current price of AGEN is $8.24 USD — it has increased by +0% in the past 24 hours. Watch Agenus stock price performance more closely on the chart.
What is Agenus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Agenus stocks are traded under the ticker AGEN.
Is Agenus stock price growing?▼
AGEN stock has risen by +7.57% compared to the previous week, the month change is a +5.91% rise, over the last year Agenus has showed a +90.3% increase.
What is Agenus market cap?▼
Today Agenus has the market capitalization of 370.88M
When is the next Agenus earnings date?▼
Agenus is going to release the next earnings report on November 10, 2026.
What were Agenus earnings last quarter?▼
AGEN earnings for the last quarter are -0.01 USD per share, whereas the estimation was 0.05 USD resulting in a -122.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Agenus revenue for the last year?▼
Agenus revenue for the last year amounts to 114.2M USD.
What is Agenus net income for the last year?▼
AGEN net income for the last year is -101,000 USD.
How many employees does Agenus have?▼
As of September 05, 2026, the company has 81 employees.
In which sector is Agenus located?▼
Agenus operates in the Health & Wellness sector.
When did Agenus complete a stock split?▼
The last stock split for Agenus was on April 12, 2024 with a ratio of 1:20.
Where is Agenus headquartered?▼
Agenus is headquartered in LEXINGTON, United States.